The majority of autoimmune disease risk effects identified by genome-wide association studies (GWAS) 14 localize to open chromatin with gene regulatory activity. GWAS loci are also enriched for expression 15 quantitative trait loci (eQTLs), suggesting that most disease risk variants exert their pathological effects 16 by altering gene expression 1,2 . However, because causal variants are difficult to identify and cis-eQTLs 17 occur frequently, it remains challenging to translate this bulk observation into specific instances of a 18 disease risk variant driving changes to gene regulation. Here, we use a novel joint likelihood framework 19 with higher resolution than previous methods to identify loci where disease risk and an eQTL are driven 20 by a single, shared genetic effect as opposed to distinct effects in close proximity. We find that 21 approximately 25% of autoimmune disease loci harbor an eQTL driven by the same genetic effect, but 22 the majority of loci do not. Thus, we uncover a fraction of gene regulatory changes as strong 23 mechanistic hypotheses for disease risk, but conclude that most risk mechanisms do not involve 24 changes to basal gene expression.
independent effects in the same region 17, 18 . Several methods have been developed to identify 1 pathogenic genes within GWAS loci relying on eQTL co-localization [19] [20] [21] [22] . However, these are limited in 2 resolution to detect situations where causal variants for the disease trait and the eQTL are distinct but 3 in linkage disequilibrium.
4
Here, we present an approach to test if a GWAS risk association and an eQTL are driven by the same 5 underlying genetic effect, accounting for the LD between causal variants. Using data from ImmunoChip 6 studies of seven AID comprising >180,000 samples in total (Table S2) , we apply this approach to test if 7 associations in 272 known risk loci are consistent with cis-eQTL for genes in each region, measured in 8 three relevant immune cell populations: lymphoblastoid cell lines (LCLs), CD4 + T cells and CD14 + 9 monocytes 23,24 .
10 When associations to two traits in a locus -here, a disease trait and an eQTL -are driven by the same 11 underlying causal variant, the joint evidence of association should be maximized at the markers in 12 tightest LD with the (potentially unobserved) causal variant 18, 25 . Here, we directly evaluate the joint 13 likelihood that both trait associations are due to the same underlying causal variant ( Figure S1 ), unlike 14 previous approaches that look for similarities in the shape of the association curve over multiple 15 markers 19, 20, 26, 27 . We expect that when the underlying causal effect is shared, joint likelihood is 16 maximized when we model the same causal variant in both traits; conversely, when the underlying 17 causal variants are different, we expect maximum joint likelihood when we model their closest proxies.
18
We empirically derive the null distribution of the joint likelihood ratio statistic by comparing disease 19 associations to permuted eQTL data. The resulting P value is asymptotically conservative against the 20 null of distinct causal variants, as the likelihoods of two competing models will be further contrasted with 21 increasing sample and effect sizes (Supplementary Notes). We are thus able to directly evaluate 22 whether associations in the same genomic locus for two traits, observed in different cohorts of 23 individuals, are due to the same underlying causal variant.
24
To assess the performance of our method, we benchmarked it against coloc 19 , a well-calibrated 25 Bayesian framework that considers spatial similarities in association data across windows of markers in 26 a locus. We simulated pairs of case-control cohorts with either the same or distinct causal variants 27 driving association in each. Though both methods had excellent performance in simulations where the 28 two distinct causal variants are in complete linkage equilibrium (AUC=0.99 for both when r 2 < 0.5), 29 compared to coloc we found that our method maintained higher specificity even as the linkage 30 disequilibrium between distinct causal variants became high (AUC = 0.92 compared to 0.70 for coloc 31 when 0.7 < r 2 < 0.8; Figure S3 , Tables S3 and S4 ). In practice, our resolution becomes limited at very 32 high LD levels (r 2 >0.8), and we are unable to reliably distinguish between two causal variants in very 3 diseases, with the proportion varying from 2/40 (5%) for type 1 diabetes loci to 4/10 (40%) for ulcerative 1 colitis loci (false discovery rate < 5%; Tables 1 and 2) . Of these 57 shared effects, 43 pass even the 2 more stringent family-wise multiple testing correction (Bonferroni corrected P < 0.05). Thus, our 3 analysis reveals that in the majority of AID loci, variants causally involved in disease phenotypes do not 4 overlap variants responsible for eQTL signals. Overall, we find that only a small minority of tested 5 disease-eQTL pairs in the same locus show any evidence of a shared association, whereas >75% 6 show evidence of being driven by distinct genetic variants in the same locus ( Figure 1 ).
7
We sought to explain this lack of overlap between disease associations and eQTLs, despite their 8 frequent co-occurrence in the same loci. In particular, although our method showed good performance 9 in simulated data ( Figure S4 ), we remained concerned that this lack of overlap may be due to low 10 statistical power in the eQTL data, which come from cohorts of limited sample size. However, we find 11 that even amongst the most strongly supported eQTLs (p < 10 -5 ), <25% show evidence of shared 12 effects with disease associations. Conversely, we find strong evidence for distinct effects for the 13 majority of disease-eQTL pairs, with only a subset of comparisons being ambiguous, suggesting that 14 our method is adequately powered to detect shared effects where they exist (Figures 1a and S11-13).
15
To assess whether power affects the total number of loci, rather than eQTL, that can be resolved, we 16 looked more deeply at our significance threshold settings. We find that more liberal thresholds do not 17 increase the number of true positive results after adjusting for false positive rate, indicating that most 18 loci do not contain any gene with an eQTL consistent with the disease association (Figures 1b and 19 S14). Cumulatively, our results demonstrate that only a minority of AID risk effects drive eQTLs in the 20 three cell populations we tested, which are drawn from diverse lineages of the immune system.
21
We next focused on the subset of 57 disease/eQTL pairs in 41 loci where we could detect strong 22 evidence of a shared effect (Table 2) . We find that 51/57 (89%) of effects are restricted to one cell 23 population, indicating that tissue-specific eQTLs are important components of the molecular 24 underpinnings of disease ( Figures S5 and S6 ). The remaining six effects are detected in multiple cell 25 populations; for example, the multiple sclerosis association at rs10783847 on chromosome 12 is 26 consistent with eQTLs for the transcript of methyltransferase-like 21B (METTL21B) in both CD4 + T cells 27 and CD14 + monocytes, but not with eQTLs for the remaining 38 genes in the immediate locus ( Figure   28 2). Although METTL21B is expressed in LCLs, there is no evidence of an eQTL in this tissue within 29 1Mb from rs10783847. Similarly, for the multiple sclerosis association at rs1966115 on chromosome 8 30 and eQTLs for ZC2HC1A, and for the inflammatory bowel disease association at rs55770741 on 31 chromosome 5 and eQTLs for ERAP2, we detect a shared effect in all three cell populations. In several 32 cases we find tissue-specific shared effects despite strong eQTLs for the same gene in other tissues:
33
for TUFM and inflammatory bowel disease risk at rs12448902 on chromosome 16, we find shared 34 effects in CD4 + and CD14 + but not LCLs, where we see a TUFM eQTL at p = 0.01 (joint likelihood P = 35 0.97). For ZFP90 and ulcerative colitis risk at rs889561 on chromosome 16, we also find shared effects 36 in CD4 + and CD14 + but not LCLs, where we observe a ZFP90 eQTL at p = 0.005 that has a low 37 likelihood of shared effect with GWAS (joint likelihood P = 0.95). Instead, we find evidence of sharing 38 between disease risk and an eQTL for NFAT5 in LCLs. Thus, despite the presence of eQTLs for a gene 39 in multiple tissues, not all these effects are consistent with disease associations suggesting that 40 disease-relevant eQTLs are tissue specific.
42
Among our findings are cases where an eQTL is consistent with associations to multiple diseases. For 43 example, the ankyrin repeat domain 55 (ANKRD55) transcript encoded on chromosome 5 has an eQTL 44 in CD4 + T cells that is shared with proximal associations to multiple sclerosis, Crohn disease and 45 rheumatoid arthritis (Figure 3 , all observations are significant after Bonferroni correction). We also find transducer (IL6ST) in CD4 + T cells, which passes the false discovery rate threshold but not the more consistent with associations to both celiac disease and multiple sclerosis ( Figure S8 ), a CD14 + eQTL 1 for RGS1 on chromosome 1 is consistent with associations to both celiac disease and multiple sclerosis 2 ( Figure S9 ), and a CD14 + eQTL for UBE2L3 on chromosome 22 is consistent with associations to both 3 celiac disease and inflammatory bowel disease ( Figure S10 ). In all cases, these are the only genome-4 wide significant disease associations reported in these loci. As we consider each disease association 5 independently, these results indicate that the same underlying risk variants drive risk to multiple 6 diseases in these loci by altering gene expression, consistent with observations of shared effects 7 across diseases 7 .
9
Overall, our results suggest that some autoimmune and inflammatory disease loci are consistent with 10 eQTLs acting in specific immune cell subpopulations, which form strong mechanistic hypotheses for the 11 molecular mechanisms driving disease risk. However, these only account for a small fraction of eQTLs 12 present in disease risk loci; this suggests that abundant caution must be exercised before inferring 13 pathological relevance for an observed eQTL simply due to proximity to a disease association. Strong 
16
Previous efforts to detect shared effects between traits in specific loci rely on conditional analyses 29 or 17 indirectly leverage linkage disequilibrium to test if the shape of association peaks in the region are 18 similar 19, 26, 27, 30 . In contrast, we directly evaluate whether the data support a shared effect through joint 19 likelihood estimation. Through this direct evaluation, we are able to resolve cases where the 20 associations are proximal with higher resolution ( Figure S3 , Tables S3 and S4 ). As our method is 21 general, we suggest it may be useful in other contexts, for example in establishing if the shared 22 heritability between diseases is driven by the same underlying causal effects 31 .
23
More broadly, our results raise the question of how causal disease variants alter cell function to induce 24 risk, given the strong enrichment of disease risk signal on regions of chromatin accessibility with gene 25 regulatory potential 1 , and gene enhancers in particular 14 . We suggest that although gene regulatory 26 regions harboring risk variants are accessible in multiple immune cell subpopulations, they may control 27 gene expression in either a tissue-specific or condition-specific manner, which is not manifest in all cell 28 populations. Our results therefore reinforce the view that we must seek the appropriate cell type and 
33
Simulated dataset. We selected two loci with previously known associations to base our positive and 34 negative simulations: CD58 on chromosome 1, rs667309 associated to MS risk 32 , and ATG16L1 on 35 chromosome 2, rs2241880 associated to IBD 33 . In each, we used Hapgen 34 and phased base 36 haplotypes of the locus (2n=112, downloaded from 37 http://mathgen.stats.ox.ac.uk/impute/impute_v2.html) to simulate up to ten cohorts, each with 1,000 38 cases and 1,000 controls, and up to 90 cohorts with other causal variants (Table S1 ). We chose these 39 other variants to have a range of LD to rs667309 or rs2241880, so we could assess the LD resolution 40 of our joint likelihood method. In each cohort, we simulated genotypes for all variants within 2Mb of 41 rs667309 or rs2241880. To make the cohorts comparable to each other, we adjusted the effect sizes of 42 causal SNPs at different MAF to maintain full power in each simulated cohort.
43 44 5 treated as the primary trait (i.e. a disease GWAS) and the other as a secondary trait (i.e. eQTL). Due to 1 the nature of the coalescent forward simulation model, 7.7% of simulated cohorts showed peak 2 association to a SNP in only moderate LD with the specified causal variant (r 2 < 0.8). We kept these 3 cohorts as secondary traits only, to better capture the vagaries of resolution limits inherent in the small 4 sample size of eQTL studies. In total, we generated 1,629 cohort pairs for positive controls simulating 5 the same causal variant and 6,106, 530, and 160 cohort pairs for negative controls for which distinct 6 causal variants are separated by r 2 of 0 -0.5, 0.5 -0.7, and 0.7 -0.8, respectively.
8
Disease GWAS datasets. We downloaded association summary statistics for type 1 diabetes (T1D), 9 rheumatoid arthritis (RA), celiac disease (CEL), multiple sclerosis (MS), inflammatory bowel disease 10 (IBD), Crohn's disease (Crohn), and ulcerative colitis (UC) from ImmunoBase (immunobase.org; Table   11 S2). For MS, we used the association statistics derived from the combined cohort of discovery and 
19
As our method works best on dense genotype data, we restricted our analyses to the 188 loci 20 genotyped at high density on ImmunoChip. We excluded the Major Histocompatibility Complex (MHC) 21 locus, due to the complex landscape of selection and resulting complex LD patterns. For each disease,
22
we sought the largest published genetic mapping study and identified genome-wide significant 23 associations reported in the 188 ImmunoChip loci. We note that these reports may contain additional 24 samples, so the associations may not be genome-wide significant in the ImmunoChip studies alone.
25
We also excluded any secondary associations after conditioning on initial results, as these are 26 inconsistently reported across diseases. If multiple independent associations are reported within the 27 same ImmunoChip region for any disease, we divide the region at the mid-point between the reported 28 markers and select lead SNPs in each sub-interval separately.
29 30 eQTL dataset. We examined eQTLs in lymphoblastoid cell lines 23 (LCLs) and primary CD4 + T cells and 31 CD14 + monocytes 24 obtained from healthy donors (Table S2) 
45
distinct causal variants were defined by separation in LD space by ! < from each other. The limit of 46 genetic resolution is a user-specified parameter and was set to 0.8 in this study. We assumed that at 47 most one causal variant was present in the locus for each trait and that no samples overlap between underlying secondary trait is more likely to be same as than distinct from the variant underlying primary 1 trait, as integrated over a set of likely causal variants under a GWAS peak of primary trait:
where * is the most associated SNP for primary trait, ! ( ) and ! ( ) are the likelihood of SNP i being 6 causally associated with primary and secondary traits, respectively, and ! ! ( ) and ! ! ( ) are the sets 7 of SNPs within LD neighborhood around SNP i, as defined by
the reference LD panel and ! ! directly from the genotypes of secondary trait cohort. We used disease 9 outcome as primary trait, leveraging the larger sample size and dense genotyping, and gene 10 expression as secondary trait, taking advantage of the availability of individual genotype data.
12
We calculated the likelihood of causal association by approximating the local LD structure with pairwise 13 correlation as previously described 38, 39 . Briefly, when SNP c is the only causal variant in the locus with 
23
we estimated the profile likelihood, which simplifies to a closed form:
Thus, given association statistics for primary and secondary traits, = ! , ! , … , ! ! 27 and = ! , ! , … , ! ! , the test statistic simplifies to:
The p-value of joint likelihood is estimated by permuting phenotypes of secondary traits as under the 31 trivial null hypothesis that that there is no casual variant for secondary trait in the locus (" ! "). With 32 respect to the more likely null that distinct causal variants underlie association signals of two traits 33 (" ! "), we can show that asymptotically as the non-centrality of causal variant increases, p-values
Thus, with large enough sample or effect sizes, joint likelihood test against ! will also reject ! in favor 2 of alternative hypothesis of shared causal variant (" ! "). Further, to evaluate whether this property 3 holds for practical non-centrality values, we examined the negative controls simulating ! in ATG16L1 4 and CD58 loci, specifically, if !"#$ was highly shifted toward 1.0 ( Figure S2 ) and larger than empirically 5 estimated false positive rates as expected (Table S4 ).
7
For both simulated and real GWAS data, we applied JLIM to SNPs with data for both primary and 8 secondary traits, present in the reference LD panels, and within 100kb of the most associated marker to 9 disease ("lead SNP"). In ImmunoChip data, the analysis windows were further confined by the 10 boundaries of the fine-mapping intervals. We compared each lead SNP to eQTL data for all genes with 11 a transcription start sites (TSS) up to 1Mb from the lead SNP, and an eQTL association p < 0.05 for at 12 least one SNP in the analysis window. To minimize computational burden, we did not consider SNPs 
17
We corrected for multiple tests using false discovery rate (FDR) levels and Bonferroni correction. The
18
FDR was calculated separately for specific disease and cell type combination as: 
27
Bayesian coloc. We ran Bayesian coloc 19 using default parameter settings on both simulated and real 28 data as described for JLIM. For simulated data, we used colocalization prior p 12 values of 10 -5 or 10 -6 , 29 which are default values for higher sensitivity and higher specificity, respectively. The beta and variance 30 of beta were used for all SNPs in the analysis window in case/control mode. We calculated accuracy as 31 the area under the receiver operator curve (ROC; Figure S3 ).
33
As ImmunoChip data is only available as summary statistics, we used the minor allele frequencies from 34 non-Finnish Europeans from the 1000 Genomes Project, and quantitative beta and variance of beta 35 calculated on eQTL association data, and a colocalization prior p 12 = 10 -6 . We did not consider the type 36 1 diabetes data, where case/control sample size is limited after excluding affected sib pair data.
38
Estimating the number of disease GWAS loci with consistent eQTL effects. We expect JLIM p-39 values to follow a bimodal distribution with modes close to zero and one when the data support a model 
To estimate the number of disease GWAS loci that can be explained by consistent effect of same 5 causal variant on disease and eQTL (denoted by below), we incrementally relaxed the p-value cut-6 offs of JLIM and examined the trends of the number of disease loci with at least one JLIM hit and 7 subtracted the expected number of false positive loci (Figures 1 and S14) . Specifically, at each JLIM p-8 value cutoff ! , we successively calculated ! : 9 10 
19
As the true null is mixture of two nulls, ! and ! , the false positive rate of JLIM against true null 20 ≥ ! ∪ ! can be bounded by using the following decomposition: 21 22 Table 1 . Only a minority of disease associations share causal variants with eQTLs across three immune cell subpopulations. We identified 261 disease associations in ImmunoChip regions with at least one eQTL within 100kb of the most associated SNP. Only 41/261 (16%) of these associations show evidence of a shared effect with an eQTL in that region. Thus, while eQTLs are abundant in disease-associated loci, they do not appear to be driven by the same causal variant as the disease association. a We only consider associations reported at genome-wide significant levels and overlapping genomic regions densely genotyped on ImmunoChip, excluding conditional peaks and MHC loci (see Methods). b eQTLs are selected if there is nominal association (eQTL p < 0.05) to at least one SNP within 100kb of the most associated SNP to disease, and a transcription start site of the gene within 1Mb of that SNP. c Number of loci where disease association is consistent with a shared effect for at least one eQTL (FDR < 5%). Table 2 . Forty one loci harbor eQTLs driven by the same variants as an association to at least one of seven diseases. We find 57 instances of shared disease-eQTL effects in 41 loci (joint likelihood of shared association FDR < 5%). a Variant with the minimum association p value to disease in the ImmunoChip summary statistics. b Minimum eQTL p value for any SNP within 100kb of the lead SNP. Dashes (-) indicate genes that are either not detected or with minimum eQTL P > 0.05 in that cell type. c Highlighted in bold are disease-eQTL pairs with false discovery rate < 5%. Asterisk (*) marks eQTL genes passing Bonferroni correction. We find strong evidence that approximately 75% of eQTLs are driven by distinct causal variants (orange) to 261 disease risk associations across 155 ImmunoChip regions. The strength of eQTL association does not influence the proportion of shared effects (green) we are able to detect, suggesting this lack of overlap is not due to lack of power. We find no compelling evidence for either shared or distinct associations for a small proportion of disease-eQTL pairs (gray). (b) The median number of loci with at least one shared effect eQTL in any tissue (blue line) at more liberal significance thresholds remains constant after false positive adjustment, further supporting this conclusion. The shaded area represents the lower and upper expectation bounds for disease-eQTL pairs driven by the same causal variant. Only 31-57% of multiple sclerosis associations and 37-57% of inflammatory bowel disease associations are consistent with eQTL effects. Equivalent data for the other diseases are presented in Figure S14 . 
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